Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Portfolio by asset class
Portfolio by asset class — Corporate debt securities & commercial paper ($M) ($M)
Moderna Portfolio by asset class: $2,440M in Q2 2026, down 15.8% from a year earlier.
Latest, Q2 2026
2,440
Period ended Jun 30, 2026
Change on a year earlier
-15.8%
2,899 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
21
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 5 (Fair Value Hierarchy).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Portfolio by asset class — Corporate debt securities & commercial paper ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,440 | -15.8% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,978 | -11.6% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,163 | -15.9% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,525 | -36.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,899 | -32.4% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,367 | -33.6% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,763 | -31.3% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 3,975 | -20.7% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,286 | -17.6% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,072 | -15.8% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,480 | -14.0% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,012 | -14.4% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 5,200 | -19.0% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 6,024 | +8.6% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 6,369 | +82.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 5,854 | +98.2% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 6,416 | +203.9% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 5,548 | – | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,488 | +94.6% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 2,953 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 2,111 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,792 | – | Form 10-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). Moderna Portfolio by asset class ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/afs-corp-debt
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.